The rates of PD-L1 expression were 90% (36/40) for oral melanoma, 70% (7/10) for OS, 60% (6/10) for HSA, 60% (3/5) for grade III MCT, 80% (4/5) for mammary adenocarcinoma, and 60% (3/5) for prostate adenocarcinoma (Table 1). Here, ALB is linked to prostate adenocarcinoma.